Zhou et al showed that CD133, a stem cell marker, could be sialylated in neural stem cells and glioma-initiating celles and sialylation regulated the protein stability of CD133 suggesting the control of stemness by protein sialylation [29]. The gene discussed is PROM1; the disease is central nervous system cancer.